- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
The Zablocki VAMC Grand Rounds focuses on medical and healthcare issues that are prevalent or particularly relevant to veterans. From that universe of topics, we encourage case-based presentations that provide updates on areas where medical care or healthcare/system organization is changing/evolving; or where outcomes indicate opportunities for improvement. For example, in the coming year, we plan to include presentations on the Wisconsin prescription drug monitoring program and treatment of chronic pain [new national VA directive this year requiring infomred consent for long term opiate therapy], obesity treatment/MOVE program [prevalent condition and VA specific treatment program], new therapies for multiple sclerosis and hepatitis C [more prevalent in veteran patients and significant advances in therapies], infection control measures [Zablocki VA recently designated as regional VA Ebola center]; patient abuse/neglect [VA-specific procedures for investigating/reporting]; addiction treatment [prevalent condition in veteran patients]; management of delirious/demented patients, and suboptimal completion percentages for advance directives..
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live Activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- Allied Health Professionals
1. Review the mechanisns of neuropathic pain and how cancer and chemotherapy can influence both central and peripheral neuropathy.
2. Review first and second line pharmacotherapy for neuropathic pain.
3. Explore differences in first line reommendations for general neuropathic pain versus chemotherapy induced peripheral neuropathy.
4. Discuss common complementary and alternative treatments for neuropathic pain.
Planning Committee Members: Jerome Van Ruiswyk, MD., FACP, FACHE, Associate Chief of Staff for Education; Annette Severson, EdD, RN, Associate Chief Nurse for Education and Research; Heather Smith, Ph.D, Psychology; Angie Paniagua, PharmD, CGP, Clinical Coordinator for Pharmacy Program; Jill Schneidermeyer, MSW, Social Work Executive; and Coordinator: Karen Hartzell, Mngt. Assistant to the Associate Chief of Staff for Education.
All persons in control of content have NO relevant financial relationships to disclose.